JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis
Myelofibrosis (MF) is a myeloproliferative neoplasm hallmarked by uncontrolled blood counts, constitutional symptoms, extramedullary hematopoiesis, and an increased risk of developing acute myeloid leukemia. Janus kinase (JAK) inhibitors are the most common treatment for MF due to their ability to r...
Na minha lista:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Innovative Healthcare Institute
2021-08-01
|
| coleção: | Journal of Immunotherapy and Precision Oncology |
| Assuntos: | |
| Acesso em linha: | https://jipo.org/doi/pdf/10.36401/JIPO-20-36 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|